Skip to main content
OpenTrials

Clinical trial condition

Dwarfism

Explore clinical trials studying Dwarfism. Study availability and eligibility vary by location and protocol.

231 public trials 35 recruiting studies
Refine in advanced search Browse all conditions

Dwarfism trial results

Completed

Safety and Efficacy Study of MOD-4023 to Treat Children With Growth Hormone Deficiency

NCT03874013

Conditions
Bone Diseases, Bone Diseases, Developmental, Bone Diseases, Endocrine, +11 more
Locations
  • Aichi Medical University Hospital Nagakute, Aichi-ken, Japan
  • Seirei Sakura Citizen Hospital Sakura, Chiba, Japan
  • Hospital of the University of Occupational and Environmental Health Kitakyushu, Fukuoka, Japan
  • Gunma University Hospital Maebashi, Gunma, Japan
View all 46 locations
View Trial Details
Completed

Lifetime Impact Study for Achondroplasia

NCT03872531

Conditions
Achondroplasia, Bone Diseases, Bone Diseases, Developmental, +5 more
Locations
  • Hospital de Pediatría "Prof. Dr. Juan P. Garrahan" Buenos Aires, Argentina
  • Instituto Nacional Fernandes Figueira (IFF), Fundacao Osvaldo Cruz Rio de Janeiro, Brazil
  • Centro de Pesquisa Clínica do Instituto da Criança HC - FMUSP São Paulo, Brazil
  • Fundacion Cardioinfantil-instituto de cardiologia Bogotá, Colombia
View Trial Details
Completed

Lifetime Impact of Achondroplasia Study in Europe-LIAISE

NCT03449368

Conditions
Achondroplasia, Bone Diseases, Bone Diseases, Developmental, +5 more
Locations
  • Medizinische Universitat Wien Vienna, Austria
  • Aarhus Universitetshospital Aarhus, Denmark
  • Klinik für Kinder- und Jugendmedizin Cologne, Germany
  • Medizinische Fakultät, Universitätskinderklinik (KPAE) Magdeburg, Germany
View all 13 locations
View Trial Details
Completed

A Trial Investigating the Safety, Tolerability, Availability and Distribution in the Body of Once-weekly Long-acting Growth Hormone (Somapacitan) Compared to Once Daily Norditropin NordiFlex® in Adults With Growth Hormone Deficiency

NCT01706783

Conditions
Adult Growth Hormone Deficiency, Bone Diseases, Bone Diseases, Developmental, +12 more
Locations
  • Novo Nordisk Investigational Site Århus C, Denmark
  • Novo Nordisk Investigational Site København Ø, Denmark
  • Novo Nordisk Investigational Site Odense, Denmark
  • Novo Nordisk Investigational Site Stockholm, Sweden
View Trial Details
Completed

Trial to Compare the Efficacy and Safety of NNC0195-0092 (Somapacitan) With Placebo and Norditropin® FlexPro® (Somatropin) in Adults With Growth Hormone Deficiency.

NCT02229851

Conditions
Adult Growth Hormone Deficiency, Bone Diseases, Bone Diseases, Developmental, +12 more
Locations
  • Novo Nordisk Investigational Site Birmingham, Alabama, United States
  • Novo Nordisk Investigational Site Los Angeles, California, United States
  • Novo Nordisk Investigational Site Los Angeles, California, United States
  • Novo Nordisk Investigational Site Aurora, Colorado, United States
View all 117 locations
View Trial Details
Completed

A Trial to Evaluate the Safety of Once Weekly Dosing of Somapacitan (NNC0195-0092) and Daily Norditropin® FlexPro® for 52 Weeks in Previously Human Growth Hormone Treated Japanese Adults With Growth Hormone Deficiency

NCT03075644

Conditions
Adult Growth Hormone Deficiency, Bone Diseases, Bone Diseases, Developmental, +12 more
Locations
  • Novo Nordisk Investigational Site Bunkyo-ku, Tokyo, Japan
  • Novo Nordisk Investigational Site Chiba-shi, Chiba, Japan
  • Novo Nordisk Investigational Site Fukuoka, Japan
  • Novo Nordisk Investigational Site Kagoshima, Japan
View Trial Details
Completed

A Trial to Compare the Safety of Once Weekly Dosing of Somapacitan With Daily Norditropin® FlexPro® for 26 Weeks in Previously Human Growth Hormone Treated Adults With Growth Hormone Deficiency

NCT02382939

Conditions
Adult Growth Hormone Deficiency, Bone Diseases, Bone Diseases, Developmental, +12 more
Locations
  • Novo Nordisk Investigational Site Århus C, Denmark
  • Novo Nordisk Investigational Site København Ø, Denmark
  • Novo Nordisk Investigational Site Odense, Denmark
  • Novo Nordisk Investigational Site Angers, France
View all 28 locations
View Trial Details

Related conditions